OMIC

Singular Genomics Reports Recent Highlights and Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Monday, March 18, 2024
Singular, Growth, SAN, Tissue, NGS, RNA, Proteomics, Workflow, Investment, Genomics, OMIC, Network throughput, H&E, Video game

“We ended 2023 on a strong note, shipping our largest number of quarterly instruments to-date,” said Drew Spaventa, Chairman and Chief Executive Officer of Singular Genomics.

Key Points: 
  • “We ended 2023 on a strong note, shipping our largest number of quarterly instruments to-date,” said Drew Spaventa, Chairman and Chief Executive Officer of Singular Genomics.
  • Shipped eight G4 systems in the fourth quarter of 2023, increasing the total number of commercial systems shipped to 24 as of the end of the fourth quarter of 2023.
  • Operating expenses for the fourth quarter of 2023 totaled $24.8 million, compared to $22.5 million for the fourth quarter of 2022.
  • Operating expenses included non-cash stock-based compensation of $2.7 million for the fourth quarter of 2023 and $3.1 million for the fourth quarter of 2022.

Singular Genomics to Report Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024

Retrieved on: 
Monday, March 4, 2024
Singular, OMIC, SAN, NGS

SAN DIEGO, March 04, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2023 after the market close on Monday, March 18, 2024.

Key Points: 
  • SAN DIEGO, March 04, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2023 after the market close on Monday, March 18, 2024.
  • The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
  • Investors interested in listening to the conference call may do so by dialing 1-877-545-0523 for domestic callers or 1-973-528-0016 for international callers and using conference ID 476908 approximately five minutes prior to the start time.
  • A live and archived webcast of the event will be available at investor.singulargenomics.com , in the Presentations & Events section.

Singular Genomics Showcases New G4X™ Spatial Sequencer at AGBT and Announces Significant Advances in Throughput, Quality, and Usability for G4® Sequencing Platform

Retrieved on: 
Monday, February 5, 2024
SAN, G4S, RNA, Genome Biology, OMIC, Proteomics, Tissue, NGS, F4, Medical imaging

Singular unveiled the G4X™ Spatial Sequencer as a high-throughput in situ spatial sequencing platform capable of simultaneous direct RNA sequencing, targeted transcriptomics, proteomics and fluorescent H&E from formalin-fixed, paraffin-embedded (FFPE) tissues.

Key Points: 
  • Singular unveiled the G4X™ Spatial Sequencer as a high-throughput in situ spatial sequencing platform capable of simultaneous direct RNA sequencing, targeted transcriptomics, proteomics and fluorescent H&E from formalin-fixed, paraffin-embedded (FFPE) tissues.
  • As an upgrade to the G4® Sequencing Platform, the G4X is expected to position Singular to be the only company worldwide to offer capabilities for tissue-based in situ spatial multiomics and NGS on the same instrument.
  • The G4X Spatial Sequencer is on display at the conference, alongside performance data from technology access collaborations with top academic centers.
  • Singular also announced updates to the G4, the industry-leading benchtop sequencing system for speed, flexibility, and power.

Singular Genomics Unveils G4X™ Spatial Sequencer, Transforming the Landscape of In Situ Multiomic Analysis

Retrieved on: 
Monday, February 5, 2024
Genomics, Tumor microenvironment, SAN, Protein, Workflow, Cell, RNA, Gene editing, Research, PX, Bone marrow, Haematopoietic system, OMIC, AML, Harvard Medical School, Proteomics, Associate professor, NGS, Tissue, Acute leukemia, Network throughput, Medical imaging

The G4X is designed to offer high-throughput in situ direct sequencing of RNA (Direct-Seq™), targeted transcriptomics, and proteomics profiling from formalin-fixed, paraffin-embedded (FFPE) tissues.

Key Points: 
  • The G4X is designed to offer high-throughput in situ direct sequencing of RNA (Direct-Seq™), targeted transcriptomics, and proteomics profiling from formalin-fixed, paraffin-embedded (FFPE) tissues.
  • The G4X Spatial Sequencer is designed to offer novel capabilities, stackable data streams, and unprecedented throughput for spatial profiling of tissue.
  • Its novel capabilities will include Direct-Seq, which is the sequencing of RNA molecules in situ and has the potential to open new areas of scientific discovery.
  • Singular also plans to provide G4X Spatial Sequencing Technology Access Services starting in the second quarter of 2024.

Singular Genomics Reports Instrument Shipments and Preliminary Unaudited Fourth Quarter 2023 Revenue

Retrieved on: 
Sunday, January 7, 2024
Singular, F3, OMIC, Growth, Genomics, G4, NGS, SAN

SAN DIEGO, Jan. 07, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced instrument shipments and preliminary unaudited revenue for the fourth quarter of 2023.

Key Points: 
  • SAN DIEGO, Jan. 07, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced instrument shipments and preliminary unaudited revenue for the fourth quarter of 2023.
  • The Company shipped eight G4 instruments in the fourth quarter of 2023.
  • Preliminary unaudited revenue for the fourth quarter of 2023 is expected to be approximately $1.0 million, representing growth of approximately 31% compared to $765 thousand during the fourth quarter of 2022.
  • Singular Genomics plans to release its full fourth quarter and 2023 financial results in March 2024.

Singular Genomics Reports Recent Highlights and Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 14, 2023
Singular, Investment, Genomics, NGS, G4, Research, SAN, OMIC, Mobile phone

SAN DIEGO, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the third quarter ended September 30, 2023.

Key Points: 
  • SAN DIEGO, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the third quarter ended September 30, 2023.
  • Shipped five G4 systems in the third quarter of 2023, increasing the total number of commercial systems shipped to 16 as of the end of the third quarter of 2023.
  • Operating expenses for the third quarter of 2023 totaled $24.5 million, compared to $24.7 million for the third quarter of 2022.
  • Operating expenses included non-cash stock-based compensation of $2.8 million for the third quarter of 2023 and $3.4 million for the third quarter of 2022.

Spatial OMICS Market Research Report 2023 - Global Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Monday, November 27, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Oncology, Spatial transcriptomics, DNA, Chemistry, Gene, Proteomics, Disease, Tissue, Genomics, USD, OMICS, COVID-19, Biomedical Research, Growth, FASP, Workflow, Government, OMIC, RNA, Medical imaging

The "Spatial OMICS Market Size, Share, & Trends Analysis Report By Technology (Spatial Transcriptomics, Spatial Genomics, Spatial Proteomics), By Product, By Workflow, By Sample Type, By End-use, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Spatial OMICS Market Size, Share, & Trends Analysis Report By Technology (Spatial Transcriptomics, Spatial Genomics, Spatial Proteomics), By Product, By Workflow, By Sample Type, By End-use, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global spatial OMICS market size is expected to reach USD 558.0 million by 2030.
  • The spatial OMICS field originated from hyperplexed imaging; however, key players have shifted toward the development of spatial transcriptomics solutions and products.
  • The development of novel technologies for spatial OMICS is anticipated to create lucrative opportunities for the fields of translational research as well as diagnostics.

Singular Genomics to Report Third Quarter 2023 Financial Results on November 14, 2023

Retrieved on: 
Tuesday, October 24, 2023
Singular, NGS, OMIC, SAN, Communications satellite, Broadcasting, Video game

SAN DIEGO, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the third quarter 2023 after the market close on Tuesday, November 14, 2023.

Key Points: 
  • SAN DIEGO, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the third quarter 2023 after the market close on Tuesday, November 14, 2023.
  • The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
  • Investors interested in listening to the conference call may do so by dialing 1-888-506-0062 for domestic callers or 1-973-528-0011 for international callers and using conference ID 616134 approximately five minutes prior to the start time.
  • A live and archived webcast of the event will be available at investor.singulargenomics.com , in the Presentations & Events section.

ACMI Federal Secures $75 Million DoD Contract for Munitions Campus to Strengthen Munitions Supply Chain

Retrieved on: 
Tuesday, September 26, 2023
Oregon Manufacturing Innovation Center, United States Army Research Laboratory, Private sector, Partnership, Army, Committee on the Office of the Deputy Prime Minister, Wardle, United States Department of Defense, American Center, Government, OMIC, Organization, Plant, IBR, Division, U.S. Department of Defense Strategy for Operating in Cyberspace, Ecosystem, Growth, Transport, ACMI, Arms industry, Renewable energy, Defense

Using a public-private partnership framework, the initiative will bolster the United States' manufacturing capabilities in areas vital for national defense.

Key Points: 
  • Using a public-private partnership framework, the initiative will bolster the United States' manufacturing capabilities in areas vital for national defense.
  • This pilot constitutes a core component of MCEIP's five-year roadmap designed to secure supply chain resiliency and fortify the defense industrial base.
  • "ACMI Federal is privileged to lead this critical endeavor," said John Burer, Founder of ACMI.
  • The Munitions Campus will support companies by providing a range of key resources necessary for munitions development and production, such as non-destructive inspection, explosives storage and transportation, prototype testing, and munitions manufacturing tools.

Singular Genomics to Present at the Gilmartin Group Emerging Growth Company Showcase

Retrieved on: 
Friday, September 8, 2023
Singular, OMIC, NGS, SAN, Video game, Broadcasting, Eastern Time Zone

SAN DIEGO, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced plans to participate in the virtual Gilmartin Group Emerging Growth Company Showcase.

Key Points: 
  • SAN DIEGO, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced plans to participate in the virtual Gilmartin Group Emerging Growth Company Showcase.
  • Singular Genomics’ management is scheduled to present on Thursday, September 21, 2023, at 8:30 a.m. Pacific Time / 11:30 a.m. Eastern Time.
  • Investors and other interested parties are invited to listen to a live and recorded webcast of the presentation at investor.singulargenomics.com , in the Presentations & Events section.